<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870870</url>
  </required_header>
  <id_info>
    <org_study_id>13930</org_study_id>
    <secondary_id>CP02-0860</secondary_id>
    <secondary_id>CP13-0811</secondary_id>
    <secondary_id>I5A-IE-JAEF</secondary_id>
    <nct_id>NCT00870870</nct_id>
  </id_info>
  <brief_title>A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Patients With Lung Cancer Who Have Not Received Chemotherapy Before</brief_title>
  <official_title>Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImClone LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImClone LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the number of participants whose cancer shrinks or
      disappears after treatment on the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with Stage IIIb or IV NSCLC who have not received previous chemotherapy will be
      stratified, based on disease histology (squamous versus [vs.] nonsquamous).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 30 weeks</time_frame>
    <description>ORR is equal to the proportion of participants achieving the best overall response of confirmed partial (PR) or complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Approximately 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (TTP)</measure>
    <time_frame>Approximately 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Approximately 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Adverse Events (AEs)</measure>
    <time_frame>Approximately 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-IMC-A12 (cixutumumab) Assessment</measure>
    <time_frame>22 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) at study day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) Cycle 1</measure>
    <time_frame>Approximately week 1 (Cycle 1, Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) Cycle 3</measure>
    <time_frame>Approximately week 7 (Cycle 3, Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) Cycle 5</measure>
    <time_frame>Approximately week 13 (Cycle 5, Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) at study day 1</measure>
    <time_frame>Minimum concentration (Cmin) at study day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) Cycle 1</measure>
    <time_frame>Approximately week 1 (Cycle 1, Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) Cycle 3</measure>
    <time_frame>Approximately week 7 (Cycle 3, Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) Cycle 5</measure>
    <time_frame>Approximately week 13 (Cycle 5, Day 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>GCiC + IMC-A12 (cixutumumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycles Repeat every 3 weeks for 6 cycles (18 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GCiC (Gemcitabine/Cisplatin/Cetuximab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cycles Repeat every 3 weeks for 6 cycles (18 weeks)
*Cisplatin will replace Carboplatin, GCC will change to GCiC (Patients enrolled subsequent to this change will receive cetuximab, gemcitabine, and cisplatin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m2 on Days 1 and 8 of each cycle
(First 6 cycles [18 weeks])</description>
    <arm_group_label>GCiC + IMC-A12 (cixutumumab)</arm_group_label>
    <arm_group_label>GCiC (Gemcitabine/Cisplatin/Cetuximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2 , day 1 of each cycle
(First 6 cycles [18 weeks])</description>
    <arm_group_label>GCiC + IMC-A12 (cixutumumab)</arm_group_label>
    <arm_group_label>GCiC (Gemcitabine/Cisplatin/Cetuximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-A12 (cixutumumab)</intervention_name>
    <description>6 mg/kg I.V. infusion, administered once per week (on Days 1, 8, and 15 of each cycle)
(First 6 cycles [18 weeks])</description>
    <arm_group_label>GCiC + IMC-A12 (cixutumumab)</arm_group_label>
    <other_name>Cixutumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>400 mg/m2 I.V. infusion, administered on Day 1 of Cycle 1, 250 mg/m2 once per week thereafter
(First 6 cycles [18 weeks])</description>
    <arm_group_label>GCiC + IMC-A12 (cixutumumab)</arm_group_label>
    <arm_group_label>GCiC (Gemcitabine/Cisplatin/Cetuximab)</arm_group_label>
    <other_name>Erbitux®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-A12 (cixutumumab)</intervention_name>
    <description>10 mg/kg I.V. infusion, administered once every 2 weeks
[Maintenance period]</description>
    <arm_group_label>GCiC + IMC-A12 (cixutumumab)</arm_group_label>
    <other_name>Cixutumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500 mg/m2 I.V. infusion, administered once every 2 weeks
[Maintenance period]</description>
    <arm_group_label>GCiC + IMC-A12 (cixutumumab)</arm_group_label>
    <arm_group_label>GCiC (Gemcitabine/Cisplatin/Cetuximab)</arm_group_label>
    <other_name>Erbitux®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC = 5, day 1 of each cycle
(First 6 cycles [18 weeks])
*Carboplatin will be replaced by Cisplatin</description>
    <arm_group_label>GCiC + IMC-A12 (cixutumumab)</arm_group_label>
    <arm_group_label>GCiC (Gemcitabine/Cisplatin/Cetuximab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has histologically or cytologically confirmed, Stage IIIb - IV NSCLC

          -  Has metastatic disease

          -  Has a tumor measurable according to Response Evaluation Criteria in Solid Tumors
             (RECIST)

          -  Has adequate hematologic function

          -  Has adequate hepatic function

          -  Has adequate renal function

          -  Women of childbearing potential must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry and for the duration
             of study participation

        Exclusion Criteria:

          -  Has uncontrolled brain metastases

          -  Has leptomeningeal disease

          -  Has received previous chemotherapy for NSCLC (patients who have received adjuvant
             chemotherapy are eligible if the last administration of the prior adjuvant regimen
             occurred at least 6 months prior to randomization)

          -  Receiving any other investigational agent(s)

          -  Has a history of treatment with other agents targeting the IGF or the EGF receptor

          -  Has a known allergy / history of hypersensitivity reaction to any of the treatment
             components

          -  Has poorly controlled diabetes mellitus. Patients with a history of diabetes mellitus
             are allowed to participate, provided that their blood glucose is within normal range
             (fasting glucose &lt; 160 mg/dL or below the ULN and hemoglobin A1C ≤ 7%) and that they
             are on a stable dietary or therapeutic regimen for this condition

          -  Has an uncontrolled intercurrent illness

          -  Pregnant or lactating

          -  Has a history of another primary cancer, with the exception of: a) curatively resected
             nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in situ; or c)
             other primary solid tumor treated with curative intent and no known active disease
             present and no treatment administered during the last 3 years

          -  Has superior vena cava syndrome contraindicating hydration

          -  Has current clinically-relevant coronary artery disease (New York Heart Association
             III or IV) or uncontrolled congestive heart failure

          -  Has any NCI-CTCAE Version 3.0 Grade ≥ 2 peripheral neuropathy

          -  Has significant third space fluid retention, requiring repeated drainage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E-mail: ClinicalTrials@ ImClone.com</last_name>
    <role>Study Director</role>
    <affiliation>ImClone LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <disposition_first_submitted>September 3, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 3, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 8, 2010</disposition_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumors</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Stage IIIb Metastatic Non-Small Cell Lung Cancer</keyword>
  <keyword>Stage IV Metastatic Non-Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 17, 2018</submitted>
    <returned>April 17, 2018</returned>
    <submitted>May 1, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

